This breakthrough imaging and mapping is a major improvement over existing 2D ultrasound routinely used for prostate cancer biopsies, where doctors blindly biopsy cells and roughly estimate locations during repeat procedures. Without being able to clearly see the prostate in real-time, physicians have had no choice but to gather less-than-precise data to determine treatment.
"The benefits of imaging advancements improve our ability to accurately guide tissue sampling, improve diagnosis and manage the disease progression. With Artemis we are able to more precisely treat patients based on what stage and grade of prostate cancer they have, not what we think they have. It helps us provide a smart biopsy," says Stephen Scionti, MD, Director of Prostate Cancer Ablation Surgery at the New York University School of Medicine and Langone Medical Center.
"We are delighted with the feedback we are getting from such world-renowned physicians as Drs. Lepor, Taneja and Scionti. Artemis is changing the way top prostate centers, such as the Smilow Center at NYU, think about prostate biopsies. Artemis gives doctors the first ever true biopsy management platform by helping them to visualize, plan, navigate, track, record and manage prostate biopsy results for their patients," says Brian Burr, Eigen CEO. "We are convinced that this new smart prostate biopsy is on the right track and that Artemis will play a significant role in reshaping the future of prostate biopsies and, potentially, the future of prostate cancer treatment as well."
About The Smilow Prostate Cancer Center
Copyright©2010 PR Newswire.
All rights reserved